Budget-impact analyses: A critical review of published studies

PharmacoEconomics

Volumn 27, Issue 10, 2009, Pages 807-827

  Orlewska, Ewa ^a   Gulácsi, Laszlo ^b  

^a Centre for Pharmacoeconomics   (Poland)

^b Institute of Entrepreneurship and Innovation   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BUDGET; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; HEALTH CARE; PRIORITY JOURNAL; REVIEW;

BUDGETS; COSTS AND COST ANALYSIS; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; PEER REVIEW, RESEARCH; PERIODICALS AS TOPIC; RESEARCH;

EID: 70349896043     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11313770-000000000-00000     Document Type: Review

References (50)

1. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices. Budget impact analysis. Value Health 2007 Sep-Oct; 10 (5): 336-347
2. Mauskopf J. Prevalence-based economic evaluation. Value Health 1998; 1 (4): 251-259
3. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19 (6): 609-621 (Pubitemid 32531836)
4. Commonwealth Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra (ACT): Commonwealth Department of Health and Ageing, Sep 2002 [online]. Available from URL: http://www.health.gov.au/ internet/main/publishing. nsf/Content/health-pbs-general-pubs-guidelines-index. htm/ $FILE/guidelines.pdf [Accessed 2008 Nov]
5. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa (ON): CCOHTA, 1997 Nov [online].Available from URL: http://www.acmts. ca/index.php/en/hta/reports-publications/search/publication/ 35 [Accessed 2005 Aug]
6. Academy of Managed Care Pharmacy. Format for formulary submissions, version 2.1. 2001 Apr [online]. Available from URL: http://www.fmcpnet.org/data/ resource/ Format~Version-2-1~Final-Final.pdf [Accessed 2008 Nov]
7. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004 Apr [online]. Available from URL: http://www.nice. org.uk/niceMedia/pdf/TAP-Methods.pdf [Accessed 2008 Nov]
8. Annemans L, Crott R, Degraeve D, et al. Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium. Pharm World Sci 2002; 24 (1): 5-7 (Pubitemid 34279730)
9. French guidelines for the economic evaluation of health care technologies. Paris: Collège des Économistes de la Santé, 2004 Sep [online]. Available from URL: http://www.ispor. org/PEguidelines/ source/France-Guidelines-HE-Evaluation. pdf [Accessed 2008 Nov]
10. Szende A, Mogyorosy Z, Muszbek N, et al. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards. Eur J Health Econ 2002; 3: 196-206 (Pubitemid 36406341)
11. Capri S, Ceci A, Terranova L, et al. Guidelines for economic evaluations in Italy: recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Inf J 2001; 35: 189-2001 (Pubitemid 32198569)
12. Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004; 7 (1): 1-10 (Pubitemid 38186279)
13. Guidelines for the submission of a request to include a pharmaceutical product in the national list of health services. Version 4. Jerusalem: April 2002 [online]. Available from URL: http://www.ispor.org/PEguidelines/source/ PE%20GUIDELINES-Israel.pdf [Accessed 2008 Nov]
14. Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics 2008; 26 (6): 477-495
15. Launois R, Payet S, Saidenberg-Kermanac'h N, et al. Budget impact model of rituximab after failure of one or more TNF alpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008; 75 (6): 688-695
16. Tosteson ANA, Burge RT, Marshall DA, et al. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 2008 Sep; 14 (9): 605-615
17. Danese MD, Reyes C, Northridge K, et al. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin Ther 2008 Apr; 30 (4): 775-784 (Pubitemid 351689042)
18. Krysanov IS, Kulikov AIu. Methodology of new pharmacoeconomic method 'impact on hospital budget' by the example of local hemostatic agents in abdominal surgery [in Russian]. Khirurgiia (Mosk) 2008; (3): 58-63
19. Chuck AW, Hailey D, Jacobs P, et al. Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. Int J Technol Assess Health Care 2008 Spring; 24 (2): 178-183
20. Lee WC, Yeh YC, Lacy BE, et al. Timely confirmation of gastro-esophageal reflux disease via pH monitoring: estimating budget impact on managed care organizations. Curr Med Res Opin 2008 May; 24 (5): 1317-1327
21. Mar J, Sainz-Ezkerra M, Miranda-Serrano E. Calculation of prevalence with Markov models: budget impact analysis of thrombolysis for stroke. Med Decis Making 2008 Jul-Aug; 28 (4): 481-490 (Pubitemid 351989994)
22. Guest JF, Valovirta E. Modelling the resource implications and budget impact of new reimbursement guidelines for the management of cow milk allergy in Finland. CurrMed Res Opin 2008 Apr; 24 (4): 1167-1177 (Pubitemid 351579176)
23. Noskin GA, Rubin RJ, Schentag JJ, et al. Budget impact analysis of rapid screening for Staphylococcus aureus colonization among patients undergoing elective surgery in US hospitals. Infect Control Hosp Epidemiol 2008 Jan; 29 (1): 16-24
24. Heeg BMS, Antunes J, Figueira ML, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Curr Med Res Opin 2008 Feb; 24 (2): 349-358 (Pubitemid 351294384)
25. Kondo M, Hoshi SL, Ishiguro H, et al. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat 2008 Nov; 112 (1): 175-187
26. Ehlers L, Müskens WM, Jensen LG, et al. National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine inDenmark: amodel of budgetary impact and cost effectiveness. CNS Drugs 2008; 22 (1): 73-81 (Pubitemid 350243368)
27. Dal Negro R, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2 (2): 169-176
28. Walt JG, Wilensky JT, Fiscella R, et al. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis. Clin Drug Investig 2007; 27 (12): 819-825 (Pubitemid 350145435)
29. Machado M, Iskedjian M, Ruiz IA, et al. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses. Pharmacoeconomics 2007; 25 (11): 979-990 (Pubitemid 350014530)
30. Spiegel BM, Esrailian E, Eisen G. The budget impact of endoscopic screening for esophageal varices in cirrhosis. Gastrointest Endosc 2007 Oct; 66 (4): 679-692 (Pubitemid 47495910)
31. Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy: a decision analysis. Aliment Pharmacol Ther 2007 Oct 15; 26 (8): 1147-1161 (Pubitemid 47480963)
32. Malone DC. A budget-impact and cost-effectiveness model for second-line treatment of major depression. J Manag Care Pharm 2007 Jul; 13 (6 Suppl. A): S8-18
33. Berto P, Gallio D, Principi N. Budgetary impact of pneumococcal conjugate vaccination of newborns [in Italian]. Ann Ig 2007 May-Jun; 19 (3): 281-291
34. Castillón Vela IT, Redondo González E, Linares Quevedo AI, et al. Outpatient female stress urinary incontinence surgery: budget impact study [in Spanish]. Arch Esp Urol 2007 Apr; 60 (3): 267-272
35. Araújo DV, Lima VC, Ferraz MB. Impact analysis of drug-eluting stent in the unified health system budget. Arq Bras Cardiol 2007 Apr; 88 (4): 458-463
36. Izuel Rami M, Gómez Barrera M, Villar Fernández I, et al. Budget impact analysis of a blood saving program for urgent traumatological surgery [in Spanish]. Med Clin (Barc) 2007 Jan 13; 128 (1): 7-11
37. Casado Gómez MA, Alvarez-Rubio L, Miró Manero S, et al. Budget impact analysis of the treatment of chronic hepatitis C in a hospital [in Spanish]. Farm Hosp 2006 Sep- Oct; 30 (5): 291-299
38. Ackroyd R, Mouiel J, Chevallier JM, et al. Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries. Obes Surg 2006 Nov; 16 (11): 1488-1503
39. Caro JJ, Huybrechts KF, Xenakis JG, et al. Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials. Curr Med Res Opin 2006 Nov; 22 (11): 2233-2242
40. Russell S, Antoñanzas F, Mainar V. Economic impact of the taxus coronary stent: implications for the Spanish healthcare system. Rev Esp Cardiol 2006 Sep; 59 (9): 889-896
41. Ramsey SD, Clarke L, Kamath TV, et al. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a US health insurance plan. JManag Care Pharm 2006 Jul-Aug; 12 (6): 472-478 (Pubitemid 47400588)
42. Spiegel BM, Dulai GS, Lim BS, et al. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol 2006 Aug; 4 (8): 988-997
43. Buti M, Casado MA, Fosbrook L, et al. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics 2005; 23 (10): 1043-1055
44. Smith DG, Cerulli A, Frech FH. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clin Ther 2005 Jun; 27 (6): 951-959
45. Sørensen J, Andersen LS. The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. Pharmacoeconomics 2005; 23 (3): 289-298 (Pubitemid 40663634)
46. Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. J Manag Care Pharm 2005 Jan-Feb; 11 (1): 66-73
47. Bloom MA, Barghout V, Kahler KH, et al. Budget impact of tegaserod on a Managed Care Organization formulary. Am J Manag Care 2005; 11: S27-34
48. Marchetti M, Caruggi M, Colombo G. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clin Ther 2004 Sep; 26 (9): 1546-1561 (Pubitemid 39572164)
49. Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of art. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5 (1): 65-79 (Pubitemid 40590125)
50. United States National Library of Medicine; National Institutes of Health. International Committee of Medical Journal Editors (ICMJE) uniform requirements for manuscripts submitted to biomedical journals: sample references [online]. Available from URL: http://www.icmje.org/ [Accessed 2009 Aug 24]